Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 2328

Surface-Modified Circuits for Blood Modification

Inventors: Daniel Kohane, Boaz Mizrahi, James McAlvin

Invention Types: Medical Device

Research Areas: Oncology/Hematology

Keywords: Medical Device, Patient Care, Polymer

For More Information Contact:  Khunkhun, Rajinder

 

Invention Description:

Sepsis represents an uncontrolled inflammatory response incited by infection. Inflammatory cytokines such as TNF-a, IL-1ß, IL-6, VEGF, and many more have been implicated as the culprits for the sepsis syndrome and its associated features. Attempts to modulate the inflammatory cascade have been largely unsuccessful, including trials of corticosteroids, antiendotoxin antibodies, TNF-a antagonists, IL-1 receptor antagonists, ibuprofen, and extracorporeal blood modification. One reason for their failure may be that the pathophysiology of sepsis syndrome changes over time. The early phase is characterized by a surge of inflammatory cytokines and the later phase shifts toward an immunosuppressive state developing and is mediated by anti-inflammatory cytokines.


Based on the above information, the Kohane laboratory is developing immune-modulating extracorporeal circuits for sepsis that selectively filter deleterious cytokines. These circuits are highly selective and their effect is limited to the time that they are in use (i.e. during the appropriate phase of the sepsis syndrome). To treat the patient, blood is flowed through the device where cytokines are removed and the cleansed blood then flows back into the body.

Applications:

• Treatment of sepsis (and other inflammatory diseases) through a device that removes cytokines from the blood

• Devices could be adapted to clear bacteria from septicemic patients

Competitive Advantages:

• Current treatments of sepsis have seen failures because the pathophysiology of sepsis syndrome changes over time. The early phase is characterized by a surge of inflammatory cytokines and the later phase shifts toward an immunosuppressive state. |
• This device overcomes the pathophysiological changes by offering selective and time-limited binding of target molecules adapted to the appropriate phase of the sepsis syndrome.

Business Opportunity:

Sponsored research or license for development of the therapeutic

IPStatus: Pat. Pend.